Press Releases
To stay up to date with our development, sign up for a subscription.
2024
2024-04-15 21:02
“During the year 2023, Sedana Medical took several important steps towards becoming a stronger and healthier company. We have returned to consistent sales growth after the challenging post-Covid period, we have taken decisive steps towards reaching...
2024-04-05 08:00
According to the financial calendar, Sedana Medical plans to publish the interim report for the first quarter 2024 on Thursday April 25 at approximately 07.00 CET. Sedana Medical hereby invites to a presentation of the report on the same day, where the...
2024-02-15 07:00
Fourth quarter 2023 January-December 2023 CEO comments Full year sales at upper end of financial guidance and an exciting year ahead Reflecting on the progress we have made during the year 2023, I am pleased to see that Sedana Medical stands as a much...
2024-01-25 08:00
According to the financial calendar, Sedana Medical plans to publish the fourth quarter and year-end report for 2023 on Thursday February 15 at approximately 07.00 CET. Sedana Medical hereby invites to a presentation of the report on the same day, where...
2023
2023-12-20 08:00
The submission is based on the results of the IsoCOMFORT trial, a randomised active-controlled assessor-blinded study comparing the efficacy and safety of sedation with inhaled isoflurane, administered via the company’s medical device Sedaconda...
2023-11-22 08:00
In 2021, Sedana Medical’s proprietary pharmaceutical Sedaconda (isoflurane) received its first market authorization in Europe for administration via the medical device Sedaconda ACD for inhaled sedation of mechanically ventilated patients in intensive...
2023-11-16 08:00
IsoCOMFORT was a randomised active-controlled assessor-blinded study comparing the efficacy and safety of sedation with inhaled isoflurane, administered via the company’s medical device Sedaconda ACD-S, with intravenous midazolam in mechanically...
2023-10-26 07:00
Third quarter 2023 January-September 2023 CEO comments All-time-high Q3 sales and further steps towards ex-US profitability We are looking back on another eventful quarter, in which we remained fully focused on our three strategic priorities: to grow...
2023-10-24 08:00
The composition of the Nomination Committee has now been established, and Sedana Medical today announces that the Nomination Committee for the 2024 Annual General Meeting consists of: The Nomination Committee represents 28,72 per cent of all voting rights...
2023-10-23 08:00
The SESAR trial, comparing sevoflurane via the Sedaconda ACD with intravenous propofol for up to 7 days is led by professor Matthieu Jabaudon and his team from Clermont Ferrand, France. The patient population consists of 700 adult patients with moderate...